A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
← catalyst calendarNCT06568627 · readout ≤ 133 d
Sponsored by MediWound Ltd (industry) · MDWD — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
216estimated
Sites
25
Countries
Austria, Germany, Israel +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-01 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Venous Leg Ulcer (VLU)
Interventions
- Drug: EscharEx (EX-03) — also filed as EX-03
- Drug: Placebo (Gel vehicle) — also filed as Gel vehicle
Primary outcomes
what the primary-completion date above is the date OFIncidence of complete debridement, clinically (visually) assessed after each application
measured up to 2 weeks
Facilitation of wound closure, clinically assessed, as measured by time to complete wound closure
measured up to 12 weeks
Permalink · MDWD's whole pipeline · Catalyst calendar · Every registered study · What changed